| | Mediators | Receptors | Drugs |
| | Histamines | Histamine receptors
(H1R, H2R, and H4R) | Antihistamines | | 5-Hydroxy tryptamine (5-HT) | 5-HT receptors
(5-HT2 and 5HT3) | Paroxetine, Fluoxetine, Mirtazapine, Ondansetron | | Proteases | Proteases-activated receptors
(PARs, PAR1–4) | Leupeptin, E6005, E-64, Chymostatin | | IL-2, IL-3, IL-4, IL-6, and IL-10 | IL-2 and IL-6 receptors | Cyclosporine, Dupilumab, Lebrikizumab | | Bradykinin | Bradykinin receptors
(B1R and B2R) | Icatibant, Bromelain | | Substance-P (SP) | NK receptor
(NKR1) | Aprepitant, Fosaprepitant, Casopitant, Vestipitant, Orvepitant, Lanepitant, Dapitant, L-733, 060 | | Calcitonin gene related peptide (CGRP) | CGRP receptors
(CALCRL and RAMP1) | Erenumab, Fremanezumab, Galcanezumab | | Opioid peptides | μ-receptor, κ-receptor | Naloxone, Naltrexone, Nalfurafine | | Cannabinoids | Cannabinoid receptors
(CB1 and CB2 receptors) | Palmitoylethanolamine (PEA) | | Leukotrienes (LTs) | Leukotriene receptors | Zafirlukast, Pranlukast, Montelukast | | Platelet-activating factor (PAF) | PAF receptor | Rupatadine, Apafant |
|
|
